Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study

<b>Objective</b>: The effectiveness and safety of belimumab in Chinese lupus patients with different disease activities were investigated in a real-world setting. <b>Method</b>: Patients who received 10 mg/kg belimumab intravenously on weeks 0, 2, and 4, and then every 4 weeks on a background of sta...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Fangfang Sun, Huaxiang Wu, Zitao Wang, Tong Wu, Xue Wu, Jie Chen, Danting Zhang, Chunde Bao, Nan Shen, Lijun Wu, Jing Zhu, Shuang Ye
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2023-03-01
Цуврал:	Biomedicines
Нөхцлүүд:	systemic lupus erythematosus (SLE) SLE Responder Index 4 (SRI-4) Lupus Low Disease Activity State (LLDAS) remission disease flare
Онлайн хандалт:	https://www.mdpi.com/2227-9059/11/3/962
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!